insights_auto
Perché LONA è in calo 17,89%?
Approfondiscichevron_right
LONA:NASDAQ
Athira Pharma
2,02 USD
arrow_downward
-17,89%(-0,44) 1G
20 nov, 16:00:04 GMT-5 · USD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per LONA in corso…
Apertura
2,36 USD
Massimo
2,48 USD
Minimo
1,91 USD
Cap. mercato
26,41 Mln
Vol. medio
71,53K
Volume
68,87K
Max 52 sett.
14,19 USD
Min 52 sett.
1,91 USD
Utili per azione
-19,72 USD
Beta
1,91
Azioni in circolazione
13,08 Mln
N. di dipendenti
19
Apertura
2,36 USD
Massimo
2,48 USD
Minimo
1,91 USD
Cap. mercato
26,41 Mln
Vol. medio
71,53K
Volume
68,87K
Max 52 sett.
14,19 USD
Min 52 sett.
1,91 USD
Utili per azione
-19,72 USD
Beta
1,91
Azioni in circolazione
13,08 Mln
N. di dipendenti
19
Articoli giornalistici
Da fonti web e partner giornalistici
Benzinga
·
31 minuti fa
Dow Jones and S&P 500 Outlook: Top Stock Market Headlines and Data This Week
The Motley Fool
·
7 ore fa
The S&P 500 Is 14 for 14 After Midterm Elections. Here’s How I’d Invest Now.
24/7 Wall St.
·
18 ore fa
His Indexed Annuity Tracks the S&P 500. The Fine Print Says "Price Return," Which Means It Leaves Out Every Dividend the 500 Companies Pay
FXEmpire
·
1 giorno fa
Previsioni Dow Jones e Nasdaq: Azioni in Calo per i Timori sulla Spesa per l’IA
Profilo
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Informazioni su Athira Pharma
CEO-
Dipendenti19
Data di fondazione2011
SedeBothell, Washington, Stati Uniti
SettoreHealth Care
Settore-
Sito webleonabio.com